Australia's Prescient Therapeutics surges on clinical study expansion

Prescient Therapeutics

09/05/2022 06:12

** Shares of clinical stage oncology co Prescient
Therapeutics Ltd  PTX.AX  rise as much as 38% to A$0.173, their
highest since March 22
    ** Stock posts its biggest intraday pct gain since July 21,
2020 
    ** Co says to expand cohort of its Phase 1b clinical study
of PTX-200 and cytarabine in patients with refractory acute
myeloid leukemia, a cancer of bone marrow that prevents
formation of normal blood cells  urn:newsml:reuters.com:*:nASX5NmFGJ
    ** Announcement follows remission in another patient, taking
the complete remissions on study up to four
    ** To expand cohort to three additional patients at same
dose level
    ** More than 8.1 mln shares change hands, compared with the
30-day average volume of 1.3 mln 
    ** Stock down 45.7% this year, as of last close

 (Reporting by Anan Ashraf)
 ((Anan.Ashraf@thomsonreuters.com;))